Oral @entity1160 Supplementation Reduces Radiotherapy- induced @entity2910 in XXXX @entity1 .

@entity1 @entity137 @entity353 @entity1160 @entity2910 @entity2 @entity7647
BACKGROUND: The purpose of this study was to assess the the efficacy of oral @entity1160 ( @entity7647 ) in prevention of acute radiation-induced @entity2910 in @entity1 with @entity2 and determine the predictive role of clinical and dosimetric parameters. MATERIALS AND METHODS: Thirty-two @entity1 diagnosed with @entity2 were studied prospectively. Sixteen @entity1 (50%) received prophylactic powdered @entity7647 orally in doses of 10g/8h. @entity1 were treated 2 Gy per fraction daily, 5 days a week. We evaluated the grading of @entity2910 daily at the end of each fraction of each treatment day until a cumulative dose of 50 Gy was reached. The primary end point was radiation-induced @entity2910 . RESULTS: All @entity1 tolerated @entity7647 well. @entity137 grade, @entity353 , serum cytokine levels and esophageal transit times exhibited statistically significant improvement in the @entity7647 receiving group. @entity7647 suppressed the inflammation related to the disease and treatment and reduced @entity137 with statistical significance. CONCLUSIONS: This study suggests a benefical role of oral @entity7647 use in prevention and/or delay of radiation-induced @entity2910 , in terms of esophageal transit time and serum immunological parameters, as well as @entity353 .
